This outcome aligns with our previous concerns that cancer cells acquiring resistance to KRAS G12C inhibitors may also develop cross-resistance to SHP2 inhibitors as well as other inhibitors targeting upstream or downstream of the RAS signaling pathway. Here, KRAS is linked to cancer.